Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02252536 · ClinicalTrials.gov registry record · Phase 2

HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder

A Phase 2 study of Alcohol Use Disorder, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Completed
Registry status
Phase 2
Development phase
346
Enrollment target
10
Study locations

NCT02252536 is a Phase 2 study of Alcohol Use Disorder that has completed, run by National Institute on Alcohol Abuse and Alcoholism (NIAAA). The registered enrollment target is 346 participants, roughly in line with the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target. The trial reports 10 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02252536, a Phase 2 study of Alcohol Use Disorder, has completed, sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA).

COMPLETED
Registry status
Phase 2
Development phase
346 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to determine whether gabapentin enacarbil is effective in the treatment of problems with alcohol.

Conditions Studied

Alcohol Use Disorder

Interventions

  • DRUG Placebo
  • DRUG gabapentin enacarbil

Study Locations (10)

California

  • University of California Los Angeles - Los Angeles
  • Friends Research Institute - San Francisco

Florida

  • University of Miami, Miller School of Medicine - Miami

Maryland

  • Johns Hopkins University School of Medicine - Baltimore

Massachusetts

  • Boston University Medical Center - Boston

New Hampshire

  • Dartmouth-Hitchcock Medical Center - Lebanon

New York

  • Mount Sinai St. Luke's Hospital - New York

Pennsylvania

  • University of Pennsylvania - Philadelphia

Texas

  • The University of Texas Southwestern Medical Center - Dallas

Trial Details

FieldValue
Enrollment Target 346 participants
Start Date 2015-06
Est. Completion 2017-03
Phase Phase 2

Sponsor

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

93 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02252536

The ClinicalTrials.gov registry entry for NCT02252536 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 346 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target. The listed sponsor is National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02252536 reports 10 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Maryland.

Frequently Asked Questions

What is clinical trial NCT02252536 about?

NCT02252536 is a clinical study titled "HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder". The purpose of this study is to determine whether gabapentin enacarbil is effective in the treatment of problems with alcohol.

What is the current status of trial NCT02252536?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 346 participants. The study started on 2015-06. Estimated completion is 2017-03.

What conditions does trial NCT02252536 study?

This clinical trial studies the following conditions: Alcohol Use Disorder.

What interventions are being tested in trial NCT02252536?

The interventions under investigation include: Placebo (DRUG), gabapentin enacarbil (DRUG).

Who is sponsoring clinical trial NCT02252536?

This trial is sponsored by National Institute on Alcohol Abuse and Alcoholism (NIAAA), which has 93 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02252536 being conducted?

This trial has 10 study locations across California, Florida, Maryland, Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alcohol Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alcohol Use Disorder

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.